Search Results

Achaogen, headquartered in South San Francisco, announced that as part of its strategic update and corporate restructuring, it will eliminate 80 positions, or about 28 percent of staff.

Shares of South San Francisco-based Achaogen, Inc. fell more than 12 percent in Monday trading after the company signaled that it began a review of strategic alternatives that could include a sale of the company.

Achaogen also intends to submit an application for marketing authorization in the European Union in 2018.

Shares of Achaogen are down more than 19 percent in early trading after the FDA handed down a split approval and rejection of Zemdri (plazomicin) for the treatment of complicated urinary tract infections and bloodstream infection, respectively.

Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing, and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today highlighted one oral and five poster presentations about plazomicin that will be presented during the Infectious Diseases Society of America (IDSA) IDWeek™ 2018, held from October 3 to 7, 2018 in San Francisco, CA.

Shares of Achaogen are down more than 30 percent in premarket trading following the results of split support from a U.S. Food and Drug Administration panel for its lead antibiotic treatment, plazomicin, which is being developed for the treatment of adults with complicated urinary tract infections and bloodstream infections.

Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, has entered into a new secured credit facility with Silicon Valley Bank (SVB), the bank of the world’s most innovative companies and their investors.

The company announced it is seeking authorization to pursue both an auction and sale under the U.S. Bankruptcy Code.

Cipla USA Inc. (“Cipla USA”), a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited (BSE: 500087; NSE: CIPLA EQ; hereafter referred to as “Cipla”), announced the acquisition of the prescription drug ZEMDRI (Plazomicin) from Achaogen Inc. (“Achaogen”) in a Chapter 11, U.S. Bankruptcy Code auction of Achaogen’s assets